Impact of a 6-month treatment with intragastric balloon on body composition and psychopathological profile in obese individuals with metabolic syndrome

• Published in: Diabetology and metabolic syndrome Vol. 8; no. 1; p. 81
• Main Authors: Guedes, Erika P, Madeira, Eduardo, Mafort, Thiago T, Madeira, Miguel, Moreira, Rodrigo O, Mendonça, Laura Maria C, Godoy-Matos, Amélio F, Lopes, Agnaldo J, Farias, Maria Lucia F
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.12.2016; BioMed Central
• Subjects: Complications and side effects; Mental illness; Methods; Obesity; Psychological aspects; Risk factors; Weight loss; Obesity; Depression; Anxiety; Body composition; Intragastric balloon
• ISSN: 1758-5996; 1758-5996
• DOI: 10.1186/s13098-016-0197-6

The aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS). Fifty patients (aged 18-50 years) with obesity and MS were selected for treatment with IGB for 6 months. Body composition was verified with dual-energy X-ray absorptiometry (DXA) at baseline and right after IGB removal. Anxiety/depressive symptoms were assessed with the Beck Depression Inventory (BDI) and the hospital anxiety and depression scale (HADS) at baseline and after 6 months of treatment. In total, 39 patients completed the study. After 6 months, there were significant decreases in weight (11.7 ± 9.6 kg, p < 0.0001) and waist circumference (9.3 ± 8.2 cm, p < 0.0001). Weight loss was also demonstrated by DXA and corresponded to decreases of 3.0 ± 3.4% in body fat percentage, 7.53 ± 7.62 kg in total body fat, and 3.70 ± 4.89 kg in lean body mass (p < 0.001 for all comparisons). Depressive symptoms scores decreased by a mean of 4.57 ± 10.6 points when assessed with the BDI (p = 0.002) and 1.82 ± 5.16 points when assessed with the HADS-Depression (p = 0.0345). Anxiety symptoms scores decreased by a mean of 1.84 ± 4.04 points when determined with the HADS-anxiety (p = 0.0066). The decrease in body fat percentage was the parameter that best correlated with improvements in depressive (p = 0.008) and anxiety symptoms (p = 0.014). In obese individuals with MS, fat mass reduction was associated with short-term improvements in depressive and anxiety symptoms. Registered at ClinicalTrials.gov, NCT01598233.